<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04448691</url>
  </required_header>
  <id_info>
    <org_study_id>23534</org_study_id>
    <nct_id>NCT04448691</nct_id>
  </id_info>
  <brief_title>&quot;SIMULATION MODELING OF CORONARY ARTERY DISEASE: A TOOL FOR CLINICAL DECISION SUPPORT&quot;</brief_title>
  <acronym>SMARTool</acronym>
  <official_title>&quot;SIMULATION MODELING OF CORONARY ARTERY DISEASE: A TOOL FOR CLINICAL DECISION SUPPORT&quot;</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondazione C.N.R./Regione Toscana &quot;G. Monasterio&quot;, Pisa, Italy</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Turku University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Azienda USL 12 Versilia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Federico II University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institut Catala de Salut</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institute of Cardiology, Warsaw, Poland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fondazione C.N.R./Regione Toscana &quot;G. Monasterio&quot;, Pisa, Italy</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Coronary atherosclerosis (ATS) is a degenerative-inflammatory artery pathology underlying the&#xD;
      different clinical manifestations of coronary heart disease (CHD), from stable angina due to&#xD;
      constrictive plaque growth obstructing artery lumen, to acute coronary syndrome (ACS),&#xD;
      secondary to abrupt lumen occlusion by atherothrombosis at the site of a ruptured or eroded&#xD;
      plaque.&#xD;
&#xD;
      Major coronary adverse events (MACE) are known to be related to local factors, the so called&#xD;
      &quot;high risk plaque&quot; characterized by large lipid-necrotic core with a thin fibrous cap,&#xD;
      intraplaque hemorrhage, rupture, erosion, and to systemic, patient-specific, factors,&#xD;
      contributing to the atherogenic genotype/phenotype of the so called &quot;high risk patient&quot;,&#xD;
      presenting with an abnormally activated thrombogenic and/or inflammatory state or increased&#xD;
      plasma levels of atherogenic lipid species.&#xD;
&#xD;
      The huge social and economic impact of CHD in western and developing countries is primarily&#xD;
      due to the difficulty to identify and predict, in the clinical context, which &quot;high risk&#xD;
      plaque&quot; in which &quot;high risk patient&quot; will cause, independently of stenosis severity, an acute&#xD;
      coronary event such as myocardial infarction or sudden coronary death, which are often the&#xD;
      first manifestations of CHD in a large proportion of otherwise asymptomatic subjects. Plaque&#xD;
      burden, compared to stenosis, is recognized as a better predictor of ACS and coronary CT&#xD;
      angiography (CCTA) is considered as the optimal non-invasive coronary imaging modality to&#xD;
      assess and quantify plaque burden and to evaluate the functional significance of a stenosis,&#xD;
      by computationally estimating fractional flow reserve. Moreover, molecular studies of CHD&#xD;
      patients have mostly examined associations with clinical cardiovascular outcomes:&#xD;
      associations with coronary ATS assessed by quantitative CCTA may provide insight into the&#xD;
      pathophysiological role of several molecular species in plaque formation and growth, and&#xD;
      elucidate their potential role as discriminative biomarkers of CHD.&#xD;
&#xD;
      Based on these considerations, aim of this study is to collect and analyze all&#xD;
      patient-specific clinical and epidemiological data and patient phenotype and genotype&#xD;
      blood-derived molecular information, and to combine them with local high resolution&#xD;
      non-invasive CCTA imaging of actual plaque burden as well as, prospectively, of its increase&#xD;
      or de novo formation over a clinically relevant timespan. The expected result, following&#xD;
      local and systemic data integration and modeling, is to optimize early diagnosis and risk&#xD;
      stratification of CHD beyond current clinical models and scores and to help improving primary&#xD;
      and secondary prevention of MACE. The overall design of this diagnostic and prognostic&#xD;
      framework has been proposed to Horizon 2020 EU Call PHC30 and approved by the European&#xD;
      Commission (Grant Agreement PHC30-689068). The Consortium includes major clinical European&#xD;
      University Hospitals specialized in CHD imaging and treatment and the project study has&#xD;
      obtained the endorsement of the European Society of Cardiovascular Imaging.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 14, 2016</start_date>
  <completion_date type="Actual">December 30, 2017</completion_date>
  <primary_completion_date type="Actual">October 30, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>prospective study with serial CCTA</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>coronary artery disease progression assessed by CCTA</measure>
    <time_frame>6 years CCTA follow up</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">275</enrollment>
  <condition>Management/Treatment of Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>CCTA</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Suspected coronary disease patients enrolled in EVINCI trial with CCTA where recalled for follow up CCTA and blood sampling</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>CCTA</intervention_name>
    <description>requested follow up CCTA</description>
    <arm_group_label>CCTA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. male and female subjects&#xD;
&#xD;
          2. aged 45-75 years&#xD;
&#xD;
          3. caucasian population&#xD;
&#xD;
          4. submitted to CCTA for suspected CHD between 2009 and 2012 (in the context of EVINCI&#xD;
             and ARTreat FPVII studies) at the Hospitals reported in &quot;SMARTool Clinical Center&quot;&#xD;
             document and satisfying the elegibility criteria reported above&#xD;
&#xD;
          5. submitted to clinical Follow-up in the last 6 months with stable clinical conditions&#xD;
             and documented CHD or persistent intermediate/high probability of CHD&#xD;
&#xD;
          6. Signed informed consents (clinical and genetic)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Multi-vessel severe disease (3 vessels and/or LM disease with &gt;90% stenosis).&#xD;
&#xD;
          2. Severe coronary calcification (CAC score &gt; 600).&#xD;
&#xD;
          3. Having undergone surgical procedures related to heart diseases (CABG, valve&#xD;
             replacement, CRT or CRTD treatment, any surgery of the heart or arteries).&#xD;
&#xD;
          4. Documented MACE at history (myocardial infarction, severe heart failure, recurrent&#xD;
             angina) in the last 6 months with/without revascularization&#xD;
&#xD;
          5. Documented severe peripheral vascular disease (carotid, femoral)&#xD;
&#xD;
          6. Surgery of carotid and/or peripheral arteries or cerebral ischemic attack&#xD;
&#xD;
          7. History/surgery of Abdominal Aortic Aneurysm(AAA).&#xD;
&#xD;
          8. Severe Heart failure (NYHA Class III-IV)&#xD;
&#xD;
          9. LV dysfunction (left ventricle EF &lt;40%).&#xD;
&#xD;
         10. Atrial fibrillation.&#xD;
&#xD;
         11. Lack of written informed consent (clinical consent and/or genetic consent)&#xD;
&#xD;
         12. Pregnancy (evaluated by urine test) and breastfeeding&#xD;
&#xD;
         13. Active Cancer&#xD;
&#xD;
         14. Asthma&#xD;
&#xD;
         15. Severe untreated Hypertension (arterial blood pressure â‰¥ 170/110 mmHg)&#xD;
&#xD;
         16. Cardiomyopathy or congenital heart disease&#xD;
&#xD;
         17. Significant valvular disease (hemodynamically significant valvular stenosis or&#xD;
             insufficiency by echoDoppler)&#xD;
&#xD;
         18. Renal dysfunction (creatinine &gt; 1.3 mg/dL)&#xD;
&#xD;
         19. Chronic Kidney Disease (eGFR &lt; 30 ml/min/1.73 m2)&#xD;
&#xD;
         20. Hepatic failure (at least 3 of the following: albumin &lt; 3.5 g/dL; prolonged&#xD;
             prothrombin time-PT; jaundice; ascites)&#xD;
&#xD;
         21. Waldenstrom disease&#xD;
&#xD;
         22. Multiple myeloma&#xD;
&#xD;
         23. Autoimmune/Acute inflammatory disease&#xD;
&#xD;
         24. Previous severe adverse reaction to iodine contrast agent&#xD;
&#xD;
         25. Positivity at blood tests for HIV, Hepatitis B and C (CRF number 1-clinical&#xD;
             evaluation)&#xD;
&#xD;
             -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://www.smartool.eu</url>
    <description>H2020 project website</description>
  </link>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 23, 2020</study_first_submitted>
  <study_first_submitted_qc>June 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 26, 2020</study_first_posted>
  <last_update_submitted>June 23, 2020</last_update_submitted>
  <last_update_submitted_qc>June 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fondazione C.N.R./Regione Toscana &quot;G. Monasterio&quot;, Pisa, Italy</investigator_affiliation>
    <investigator_full_name>Silvia Rocchiccioli</investigator_full_name>
    <investigator_title>Project Coordinator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

